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Cefepime-related encephalopathy in peritoneal dialysis patients
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Received May 19, 2010; accepted August 21, 2010AbstractEncephalopathy or neurotoxicity can occur with cefepime use in patients with impaired or relatively normal renal function. However, few
articles have examined the relationship between cefepime’s adverse effects and peritoneal dialysis.
Here, we report the case of an 80-year-old woman with chronic renal failure on peritoneal dialysis that developed agitation, confusion, and
dystonia after cefepime administration for 2 days. The clinical and electroencephalographic abnormalities improved after discontinuation the
drug. We review the role of peritoneal dialysis in the development of cefepime-induced encephalopathy. Peritoneal dialysis is a less efficient way
to eliminate cefepime than hemodialysis. Short-term hemodialysis might be considered to facilitate elimination of the drug in patients who have
developed neurotoxicity.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Cefepime is a fourth-generation cephalosporin used to treat
severe infection, which is mainly excreted unchanged by
kidney.1,2 There were several series of cases with cefepime-
associated reversible encephalopathy or nonconvulsive-status
epilepticus in patients with variable level of impaired3e9 or
relatively normal10,11 renal function. The incidence has been
reported to be 1%. Among renal-impaired patients, the inci-
dence rose to 4.5e16.6%.12 Up to now, there have been only
four reported cases of cefepime-associated neurotoxicity in
uremic patient using continuous ambulatory peritoneal dialysis
(CAPD) as renal replacement therapy. Also, there was no
literature focusing on the role of peritoneal dialysis in the
development of such adverse events.* Corresponding author. Dr. Jong-Ling Fuh, The Neurological Institute,
Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 112,
Taiwan, ROC.
E-mail address: jlfuh@vghtpe.gov.tw (J.-L. Fuh).
1726-4901/$ - see front matter Copyright  2011 Elsevier Taiwan LLC and the C
doi:10.1016/j.jcma.2011.01.017Here, we present a case with chronic renal failure under
CAPD, who developed incompletely reversible encephalop-
athy after 2-day administration of cefepime.
2. Case report
An 80-year-old woman presented with a 3-month
progressive decline of mental status and daily living abilities.
She had a medical history including hypertension, coronary
artery disease, mild cognitive impairment, and chronic renal
failure under CAPD. On presentation, she could stand with
assistance, but could not walk. She had a score of 8 on the
Mini-Mental State Examination.
A brain magnetic resonance imaging (MRI) showed
profound leukoaraiosis. The patient was afebrile during the
hospital stay. However, initial blood tests showed leukocytosis
along with elevated C-reactive protein (CRP) level. Pneu-
monia was initially suspected, and cefmetazole 2 g/day was
empirically used for 2 weeks. Abdominal computed tomog-
raphy demonstrated fluid accumulation in the uterus. A diag-
nostic dilation and curettage confirmed the existence of
endometritis. We substituted the antibiotic regimen withhinese Medical Association. All rights reserved.
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patient’s cognitive function improved, and she could respond
functionally with single words. However, the patient devel-
oped acute delirium and refused oral intake, had no verbal
output and showed agitation on Day 2. On Day 3, she had
head-turning to the right with a dystonic posture. A follow-up
blood test showed improved white cell counts and CRP level,
but her mental status kept on worsening. All the serologicFig. 1. (A) Three days after cefepime therapy, EEG showed periodic short-interval
slow waves with 4e6 Hz; (B) Two weeks after cefepime injection, EEG showed pmetabolic analyses were normal. Antibiotic-related encepha-
lopathy was suspected and we shifted cefepime and metroni-
dazole to piperacillin/tazobactam 4.5 g/day immediately.
Electroencephalogram (EEG) showed periodic short-interval
diffuse discharges with shifting predominance on Day 4
(Fig. 1A). The consciousness level improved gradually
thereafter. The patient was responsive to verbal stimuli on Day
6 and able to obey orders intermittently on Day 7. An EEG ondiffuse discharges with shifting predominance, along with diffuse background
artial recovery.
Table 1
Clinical features of five peritoneal dialysis patients with cefepime-induced neurotoxicity
References (year) Age/sex
(yr)
Creatinine
level (mg/dL)
Cefepime
dosage
Clinical manifestation Latency (d) Treatment Outcome
Chow et al. (2001)6 69/F 14.2 2 g/d Confusion 6 AED Resolved
Chow et al. (2003)7 59/M 14.1 5 g/d Confusion, obsessive ideas, dysmetria 2 NR Resolved
60/F 9.5 1 g/d Disorientation, irrelevant speech 9 NR Resolved
Alpay et al. (2004)9 15/M NR 12.5 mg/kg/d Ataxia, asterixis, confusion 6 BZD, AED Resolved
Lin (current study) 80/F 5.6 2 g/d Confusion 2 Stop cefepime Improved
AED¼ antiepileptic drugs; BZD¼ benzodiazepine; F¼ female; M¼male; NR¼ not reported.
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epileptiform discharges (Fig. 1B). At a 2-month follow-up
evaluation, she still had not improved to the baseline level.
3. Review of literature
A literature review was performed by using PubMed with
keywords including cefepime, encephalopathy, neurotoxicity,
and peritoneal dialysis (1999e2008). There were three case
reports found, including four patients (two males and two
females). We collected information about the patients’ age of
onset, serum creatinine level, daily cefepime dosage, and
latency from initiation of treatment to onset of neurological
toxicities.
4. Results
In addition to our patient, there were only four patients
receiving peritoneal dialysis (two males and two females) who
suffered from cefepime-induced neurotoxicity reported in the
literature (Table 1), including three adults who developed
reversible encephalopathy6,7 and one 15-year-old adolescent
who suffered from nonconvulsive-status epilepticus.9
Including our patient, the median age was 60 years. The
median latency was 6 days. For the four adult cases, the
accumulative dose was 4e12 g. Our patient had the oldest age,
the shortest latency from initiation of treatment to symptoms
onset among the five cases and the lowest accumulated dose
among the four adults.
5. Discussion
Because of the temporal association of the symptom onset
and drug administration, as well as symptom improvement after
drug discontinuation, we diagnosed the patient as having anti-
biotic-related encephalopathy. Infection relatedeconsciousness
disturbance was not likely because the symptoms developed
along with improvement of white blood cell counts and CRP
level. Uremic encephalopathy was excluded because of the
stable renal function test data.
Besides cefepime, this patient was also administered with
metronidazole at the same time. However, the clinical presen-
tations of our patient were not compatible with previously
reported metronidazole-associated neurotoxicities, which
encompassed encephalopathy, cerebellopathy, and dentate
nuclei involvement demonstrated via MRI and tended to occurafter prolonged use.13 Although no affirmable causality could
be claimed, we indicated that cefepime was likely the cause of
the clinical and electroencephalographic manifestations of the
present case.
All previous cases of cefepime-related encephalopathy and
neurotoxicity, with the exception of two cases, had renal
insufficiency or failure.10,11 Except for renal function impair-
ment,12 no other independent risk factors have been reported.
The mechanisms involved in the development of such neuro-
toxicity have not been clearly understood. Decreased g-ami-
nobutyric acid releasing from nerve terminals and subsequent
increased excitatory neurotransmission,14e16 g-aminobut-
yric acid transporter system dysfunction,17 and induction of
endotoxins along with the release of tumor necrosis factor-
alfa18 have been proposed to explain the pathophysiology.
CAPD is less efficient at clearing cefepime than hemodi-
alysis. Dialytic clearance of cefepime by peritoneal dialysis is
only 9% of that reported for the hemodialysis.19 The half-life
of cefepime is approximately 2.2 hours in adults with normal
renal function1,20 but prolonged to 18 hours in CAPD
patients.19 A dosing interval of 70.7 hours had been calculated
for patients with CAPD.19 A dosing interval of 24 hours, such
as used in the present case, may cause accumulation of the
drug in plasma, peritoneal fluid, and even cerebrospinal fluid,
which in turn induces neurotoxicity. The lower clearance of
cefepime in CAPD patients may explain the slow and partial
recovery. For such high-risk patients, the dosage of renal
excreted antibiotics including cefepime should be adjusted
cautiously. There were less reported cases of penicillin-
induced encephalopathy than those due to cephalosporin.
Piperacillin/tazobactam may be an alternative agent when
broad-spectrum antibiotics are clinically necessary.
There have been some articles indicating the beneficial role
of short-term hemodialysis in treating patients suffering from
the neurotoxicity associated with cefepime.2,5 Thus, short-
term hemodialysis may provide better and more rapid
improvement of clinical status in our patient.
Reviewing all the published articles, preexisting cognitive
impairment had not been taken into account. Cefepime dose as
low as 9 g previously caused neurotoxicity in patients with
CAPD. However, our patient developed symptoms after
receiving only 4 g of cefepime. Our patient had underlying
cognitive impairment and leukoaraiosis as demonstrated by
brain MRI, which may have further contributed to the
vulnerability and poor reversibility of this episode. However,
a longer follow-up may be needed to clarify reversibility.
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